MADRID, July 10, 2025 /PRNewswire/ -- SteriLance Medical, a global leader in personal blood-sampling solutions, today launches its breakthrough Onestep™ Lancing Device and companion SoftSense™ Lancets in Spain, marking the company's entry into Europe.
Onestep is the world's first cap-free, four-step lancing pen that keeps the needle hidden from start to finish and drives it with patent-protected Total Path Control™ (TPC) vertical-drive technology, delivering virtually painless sampling while halving preparatory motions. The devices are now available in Spain through select pharmacy outlets and partner e-commerce stores, with wider European roll-out to follow.
What makes Onestep different
In a recent evaluation with 30 frequent testers, 92 % reported "little or no pain," while 87 % felt safer because they never saw the needle.
Market context
Spain is home to an estimated 5.1 million adults with diabetes, one of the highest prevalence rates in Europe. Low-pain, easy-to-use devices such as Onestep can help improve adherence to daily self-monitoring, a cornerstone of effective diabetes management.
Availability
Onestep and SoftSense are now on sale in Spain via select brick-and-mortar pharmacies and partner e-commerce sites. Broader retail and pharmacy distribution across additional EU markets will commence in the coming months.
Compliance & resources
Onestep and SoftSense are CE-MDR and ISO 13485 certified and engineered for frequent, home-based capillary sampling.For more information about Onestep and to explore its features, visit:https://en.sterilance.com/innovative_products/onestep-lancing-device.For media or distribution enquiries, please contact: smu@sterilance.com.
Photo - https://mma.prnewswire.com/media/2728413/image_5020157_8534348.jpg
Comunicato stampa sponsorizzato - Responsabilità editoriale PrNewswire. I giornalisti Adnkronos non sono in nessun modo coinvolti né responsabili per i contenuti dei comunicati trasmessi.
.jpg)
